A contraceptive subdermal implant releasing the progestin ST-1435: ovarian function, bleeding patterns, and side...

Area of Science:

• Reproductive endocrinology
• Contraceptive technology
• Clinical pharmacology

Background:

• Subdermal implants offer long-acting reversible contraception.
• The progestin ST-1435 is a novel compound for hormonal contraception.
• Evaluating new contraceptive methods is crucial for reproductive health.

Purpose of the Study:

• To assess the efficacy and safety of a novel ST-1435 contraceptive subdermal implant.
• To investigate ovarian function, bleeding patterns, and side effects during one year of use.
• To determine the contraceptive reliability of the ST-1435 implant with a two-year lifespan.

Main Methods:

• A prospective study involving 26 healthy women using a single ST-1435 implant.
• Monitoring ovarian function through serum hormone levels (ST-1435, progesterone, estradiol).
• Recording bleeding patterns and documenting all reported side effects over a 12-month period.

Main Results:

• The ST-1435 implant demonstrated high contraceptive efficacy, inhibiting ovulation in all analyzed cycles.
• No pregnancies were reported during the 302 woman-months of observation.
• Irregular bleeding and spotting were common, affecting approximately half of the users, particularly in the first year.

Conclusions:

• The ST-1435 subdermal implant provides effective contraception through ovulation suppression.
• Despite common irregular bleeding, the implant was well-tolerated, with no hormonal side effects reported.
• The high continuation rate suggests good user acceptance and tolerability of the ST-1435 implant.